Substituted pyrido[3,4-b]pyrazines as GPR6 modulators

Patent metadata

Field	Value
Publication number	US-10738046-B2
Application number	US-201816057350-A
Country	US
Kind code	B2
Filing date	Aug 7, 2018
Priority date	Dec 20, 2013
Publication date	Aug 11, 2020
Grant date	Aug 11, 2020

Abstract

The present invention provides compounds of formula I:

which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.

First claim

What is claimed is:

1. A method for modulating G-protein-coupled receptor 6 activity in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of formula I:

or a pharmaceutically acceptable salt thereof,
wherein:
R 1 is selected from the group consisting of C 3-8 cycloalkyl, C 3-6 heterocyclyl, C 6-10 aryl, and C 1-10 heteroaryl, each optionally substituted;
R 2 is selected from the group consisting of —OR 5 and —NR 6 R 7 ;
each R 3 is independently selected from the group consisting of C 1-6 alkyl, trifluoromethyl, and C 3-8 cycloalkyl;
R 5 is selected from the group consisting of C 1-6 alkyl and C 3-8 cycloalkyl;
R 6 is selected from the group consisting of hydrogen and C 1-6 alkyl;
R 7 is selected from the group consisting of C 1-6 alkyl, C 3-8 cycloalkyl, C 3-6 heterocyclyl, C 6-10 aryl, and C 1-10 heteroaryl, wherein the C 1-6 alkyl, C 3-6 heterocyclyl, C 6-10 aryl, and C 1-10 heteroaryl are each optionally substituted;
(i) X 1 is N; and
X 2 is CH; or

(ii) X 1 is CH; and
X 2 is N; or

(iii) X 1 is N; and
X 2 is N;

when X 1 is N;
Z is selected from the group consisting of C 1-6 alkylene, C 1-6 haloalkylene, —C(O)—, and —S(O) 2 —;
when X 1 is CH;
Z is selected from the group consisting of C 1-6 alkylene, C 1-6 haloalkylene, —C(O)—, —NH—, —O—, —S—, —S(O)— and —S(O) 2 —;
(iv) X 3 is selected from the group consisting of CH 2 and CHR 4 ; and
X 4 is NR 8 ; or

(v) X 3 is NR 8 ; and
X 4 is selected from the group consisting of CH 2 and CHR 4 ;

each R 4 is independently selected from the group consisting of halo, hydroxy, and C 1-6 alkyl;
R 8 is selected from the group consisting of C 1-6 alkyl, C 1-6 haloalkyl, —C(O)—R 10 , —C(O)—N(R 11 )(R 12 ), —C(O)—OR 13 , —S(O) 2 —R 9 , and C 3-8 cycloalkyl;
R 9 is selected from the group consisting of C 1-6 alkyl, C 3-8 cycloalkyl, and optionally substituted phenyl;
R 10 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, C 3-6 heterocyclyl, C 6-10 aryl, and C 1-10 heteroaryl, wherein the C 1-6 alkyl, C 3-6 heterocyclyl, C 6-10 aryl, and C 1-10 heteroaryl are each optionally substituted;
R 11 is selected from the group consisting of hydrogen and C 1-6 alkyl;
R 12 is selected from the group consisting of hydrogen, C 1-6 alkyl, and C 3-8 cycloalkyl; or
R 11 and R 12 , taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered, saturated ring, optionally having one additional ring heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur, and further optionally substituted on any of the ring carbon atoms with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of halo, hydroxy, cyano, amino, C 1-9 amide, optionally substituted C 1-6 alkyl, C 1-4 alkoxy, and optionally substituted C 3-6 heterocyclyl, and substituted on any additional ring nitrogen atom by hydrogen or a substituent selected from the group consisting of optionally substituted C 1-6 alkyl and C 3-8 cycloalkyl;
R 13 is selected from the group consisting of C 1-6 alkyl and C 3-8 cycloalkyl;
p is 0, 1, or 2;
q is 0, 1, or 2;
r is 0 or 1; and
s is 0, 1, or 2;
wherein any optionally substituted C 1-6 alkyl is optionally substituted with 1, 2, 3, 4, 5, 6 or 7 substituents independently selected from the group consisting of halo, hydroxy, cyano, amino, C 1-8 alkylamino, C 1-9 amide, C 1-4 alkoxy, C 1-5 oxycarbonyl, C 3-8 cycloalkyl, C 3-6 heterocyclyl, optionally substituted phenyl, and C 1-10 heteroaryl, wherein the C 3-6 heterocyclyl is optionally substituted on any ring nitrogen atom by C 1-4 alkyl;
wherein any optionally substituted C 3-8 cycloalkyl is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, hydroxy, C 1-4 alkyl, and C 1-4 alkoxy, wherein the C 1-4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, and C 1-4 alkoxy;
wherein any optionally substituted C 3-6 heterocyclyl is optionally substituted on the ring carbon atoms with 1, 2, 3 or 4 substituents independently selected from the group consisting of halo, hydroxy, C 1-4 alkyl, and C 1-4 alkoxy, and optionally substituted on any ring nitrogen atom with a C 1-4 alkyl;
wherein any optionally substituted phenyl is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of halo, nitro, hydroxy, cyano, amino, C 1-8 alkylamino, C 1-9 amide, C 1-4 alkyl, trifluoromethyl, C 1-4 alkoxy, C 1-5 oxycarbonyl, and C 1-8 sulfonyl
wherein any optionally substituted C 6-10 aryl is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of halo, hydroxy, cyano, amino, C 1-4 alkyl, trifluoromethyl, C 1-4 alkoxy, and trifluoromethoxy; and
wherein any optionally substituted C 1-10 heteroaryl is optionally substituted on the ring carbon atoms with 1, 2 or 3 substituents independently selected from the group consisting of oxo, halo, hydroxy, cyano, amino, C 1-8 alkylamino, C 1-9 amide, C 1-4 alkyl, trifluoromethyl, C 1-4 alkoxy, and trifluoromethoxy, and optionally substituted on any ring nitrogen atom with a C 1-4 alkyl.

2. The method according to claim 1 , wherein the subject has a condition associated with G-protein-coupled receptor 6.

3. The method according to claim 2 , wherein the condition associated with G-protein-coupled receptor 6 is selected from the group consisting of schizophrenia and depression.

4. The method according to claim 2 , wherein the condition associated with G-protein-coupled receptor 6 is selected from the group consisting of a movement disorder, a drug addiction, an eating disorder, a cognitive disorder, and a bipolar disorder.

5. The method according to claim 4 , wherein the movement disorder is selected from the group consisting of levodopa induced dyskinesia and Huntington's disease.

6. The method according to claim 1 , wherein R 1 is optionally substituted C 6-10 aryl.

7. The method according to claim 1 , wherein R 2 is —NR 6 R 7 .

8. The method according to claim 1 , wherein:
X 1 is CH; and
X 2 is N.

9. The method according to claim 1 , wherein:
X 1 is N; and
X 2 is N.

10. The method according to claim 9 , wherein:
X 3 is selected from the group consisting of CH 2 and CHR 4 ; and
X 4 is NR 8 .

11. The method according to claim 1 , wherein Z is C 1-6 alkylene.

12. The method according to claim 1 , wherein Z is —C(O)—.

13. The method according to claim 1 , wherein Z is —O—.

14. The method according to claim 1 , wherein the compound is selected from the group consisting of;
cyclopropyl(2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-(isopropylamino)-7,8-dihydropyrido[3,4-b]pyrazin-6(5H)-yl)methanone;
1-(2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-(isopropylamino)-7,8-dihydropyrido[3,4-b]pyrazin-6(5H)-yl)-2-methoxyethan-1-one;
2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-N-isopropyl-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-b]pyrazin-3-amine;
2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-(isopropylamino)-N-(2-methoxyethyl)-7,8-dihydropyrido[3,4-b]pyrazine-6(5H)-carboxamide;
2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-(isopropylamino)-7,8-dihydropyrido[3,4-b]pyrazin-6(5H)-yl)(tetrahydrofuran-2-yl)methanone;
3-(2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-(isopropylamino

Assignees

• Takeda Pharmaceuticals Co

Inventors

• Brown Jason W
• Hitchcock Stephen
• Hopkins Maria
• Kikuchi Shota
• Monenschein Holger
• Reichard Holly
• Schleicher Kristin
• Sun Huikai
• Macklin Todd

Classifications

• A61K31/4985

  Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P25/36

  Opioid-abuse · CPC title

• A61P25/30

  for treating abuse or dependence · CPC title